Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/66—Phosphorus compounds
  • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
  • C07F9/6568—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
  • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
  • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
  • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
  • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
  • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
  • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
  • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
  • C07F9/65842—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring
  • C07F9/65846—Cyclic amide derivatives of acids of phosphorus, in which one nitrogen atom belongs to the ring the phosphorus atom being part of a six-membered ring which may be condensed with another ring system

Definitions

• the subject of the present invention is novel phosphinane and azaphosphinane derivatives, process for their preparation and pharmaceutical compositions containing them.
• the compounds of the invention are inhibitors of TAFIa (activated thrombin-activatable fibrinolysis inhibitor).
• TAFI also known as plasmatic procarboxypeptidase B, procarboxypeptidase R, or procarboxypeptidase U
• TAFI is a 60 kDa plasma glycoprotein produced by the liver that circulates as a zymogen.
• thrombin and plasmin cleave the prosegment of TAFI at the Arg92-Ala93 binding to transform it into an active enzyme, TAFIa, which has a half-life of 8 to 15 minutes at 37. ° C.
• thrombomodulin a co-factor present in the plasma and on the surface of endothelial vascular cells
• TAFIa negatively regulates fibrinolysis by cleaving the C-terminal lysine residues of fibrin fibers that appear during the partial degradation of fibrin by the first traces of plasmin.
• C-terminal lysine residues on partially degraded fibrin behave as ligands of circulating plasma plasminogen and tissue plasminogen activator (tPA) generated by endothelial cells during thrombotic ischemia. They thus make it possible to localize the transformation of plasminogen to plasmin by tPA without interference with the circulating plasmin inhibitor ⁇ 2-antiplasmin or with the circulating inhibitor of tissue plasminogen activator (PAI-1). Cleavage of C-terminal lysine sites by TAFIa thus decreases the generation rate of plasmin.
• tPA tissue plasminogen activator
• TAFIa inhibitors therefore have the potential to increase endogenous and therapeutic fibrinolysis and behave as antithrombotic and profibrinolytic agents without major risk of haemorrhage since they do not interfere with platelet activation or coagulation during the treatment. blood hemostasis.
• the property of inhibition of TAFIa thus makes it possible to envisage the use of the compounds of the invention in the treatment and the prevention of thrombotic events in patients at risk.
• vascular complications especially cardiovascular, pulmonary and cerebrovascular related to atherothrombotic diseases, atherosclerosis, diabetes, hyperlipidemia, hypertension, diseases chronic veins, metabolic syndrome related to obesity or cancer.
• the compounds according to the invention are particularly useful for the treatment, prevention and secondary prevention of myocardial infarction, angina pectoris, cerebrovascular accidents, aortic aneurysms, arteritis of the lower limbs, fribrotic diseases, venous thromboses and pulmonary embolism.
• vascular risk factors and vascular diseases such as hypertension, obesity, diabetes, heart disease, cerebrovascular disease and hyperlipidemia and therefore atherosclerosis play a role in the genesis of dementia such as the disease Alzheimer's and vascular dementia (Qiu C, De Ronchi D. and Fratiglioni L., The epidemiology of the dementias: an update, 2007, Current Opinion in Psychiatry, 20: 380-385).
• the compounds of the invention will therefore also be useful for the treatment and / or prevention of dementias such as Alzheimer's disease and vascular dementia.
• TAFIa decreases the endogenous fibrinolytic potential.
• the compounds of the present invention are therefore useful for accompanying acute treatment with injectable fibrinolytics, such as recombinant tPA (e.g., alteplase, tenecteplase, reteplase, desmoteplase), recombinant uPA or streptokinase, which are used in emergency situations (eg myocardial infarction, stroke).
• injectable fibrinolytics such as recombinant tPA (e.g., alteplase, tenecteplase, reteplase, desmoteplase), recombinant uPA or streptokinase, which are used in emergency situations (eg myocardial infarction, stroke).
• the compounds of the present invention enhance the activity of these injectable fibrinolytics and therefore lead to their use with less risk haemorrhagic and neurotoxic (reduction of their dose and therefore reduction of their side effects).
• the present invention relates more particularly to the compounds of formula (I):
• Aki is an alkyl chain Ci-C 6,
• X represents - (CH 2 ) m -, -CH (R) -, -N (R) -, -CH 2 -N (R) -, -N (R) -CH 2 - or -CH 2 -N ( R) -CH 2 -, m represents 0 or an integer of 1 to 4,
• R represents a hydrogen atom or a group selected from C 1 -C 6 alkyl, -Ak 2 -Ak 2 -Ari-Ar 2 and -Ak 2 -Ari-O-Ar 2 , -Ak 2 -cycloalkyl or -Ak 2 -OH,
• Ak 2 represents a linear or branched C 1 -C 6 alkyl chain
• Ari and Ar 2 which are identical or different, each represent an aryl or heteroaryl group,
• R 1 and R 2 each represent a hydrogen atom when X is - (CH 2 ) m -, -CH (R) -, - N (R) -, -CH 2 -N (R) - or -N (R) ) -CH 2 -,
• R 3 represents NH 2 , Cy-NH 2 , Cy-Ak 3 -NH 2 or piperidin-4-yl,
• Cy represents a group chosen from cycloalkyl, aryl and heteroaryl
• Ak 3 represents a C 1 -C 3 alkyl chain
• R 4 and R 5 identical or different, each represent a hydrogen atom or a fluorine atom, their optical isomers, and their addition salts with a pharmaceutically acceptable acid.
• aryl group is meant phenyl, naphthyl or biphenyl optionally substituted with one or more groups, identical or different, selected from halogen, hydroxy, amino, alkyl (Ci-C 6) linear or branched optionally substituted by one or more halogen atoms, methylsulfonyl, methylthio, carboxy, alkoxy (Ci-C 6) linear or branched optionally substituted by one or more halogen atoms, aminoalkyl (C -C 6 ) linear or branched, the amino group of the aminoalkyl group being optionally substituted with one or two linear or branched (Ci-C 6 ) alkyl groups.
• heteroaryl group is meant an aromatic monocyclic group or a 5- to 12-membered aromatic or partially aromatic bicyclic group containing one, two or three heteroatoms chosen from oxygen, nitrogen or sulfur, it being understood that the heteroaryl may optionally be substituted with one or more groups, which may be identical or different, chosen from linear or branched halogen, hydroxy, amino, oxo, (C 1 -C 6 ) alkyl optionally substituted by one or more halogen atoms, linear (C 1 -C 6 ) alkoxy or branched chain optionally substituted by one or more halogen atoms, linear or branched (C 1 -C 6 ) aminoalkyl, the amino group of the aminoalkyl group being optionally substituted with one or two linear or branched (C 1 -C 6 ) alkyl groups.
• groups which may be identical or different, chosen from linear or branched halogen, hydroxy, amino, oxo, (C 1 -C 6 ) alky
• heteroaryl groups mention may be made, without limitation, of pyridyl, thienyl, furyl, imidazolyl, pyrimidinyl, pyrazolyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazinyl, pyridazinylbenzofuryl, benzothienyl, benzimidazolyl, imidazopyridinyl, isoquinolinyl and dihydrobenzo groups. furyl, dihydrobenzoxazolyl, dihydroindolyl, dihydroindazolyl, benzodioxolyl.
• cycloalkyl group is meant a saturated monocyclic hydrocarbon group of 5 to 7 members, it being understood that the ring may be optionally substituted by one or more groups, which may be identical or different, chosen from halogen, linear (C 1 -C 6 ) alkyl or branched.
• groups which may be identical or different, chosen from halogen, linear (C 1 -C 6 ) alkyl or branched.
• cycloalkyl groups mention may be made, without limitation, of cyclopentyl, cyclohexyl and cycloheptyl groups.
• Optical isomers are understood to mean diastereoisomers and enantiomers.
• the compounds of formula (I) have at least one asymmetric center:
• Among the pharmaceutically acceptable acids mention may be made, without limitation, of hydrochloric, hydrobromic, sulfuric, phosphoric, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, oxalic and methanesulphonic acids. benzenesulfonic acid, toluenesulfonic, camphoric.
• One aspect of the present invention relates to compounds of formula (I) wherein Aki is - (CH 2 ) 4 -.
• Another aspect of the present invention relates to the compounds of formula (I) for which X is -N (R) -.
• Another aspect of the present invention relates to compounds of formula (I) wherein X is -N (R) -, -CH 2 -N (R) -, -N (R) -CH 2 - or -CH 2 - N (R) -CH 2 -, and R represents a group selected from -Ak 2 -Ari, -Ak 2 -Ari-Ar 2 and -Ak 2 -Ari-O-Ar 2 .
• Another aspect of the present invention relates to compounds of formula (I) wherein X is -N (R) -, -CH 2 -N (R) -, -N (R) -CH 2 - or -CH 2 - N (R) -CH 2 -, R represents a group selected from -Ak 2 -Ari, -Ak 2 -Ari-Ar 2 and -Ak 2 -Ari-O-Ar 2 , and Ak 2 represents -CH 2 -.
• Another aspect of the present invention relates to the compounds of formula (I) for which R4 and R5 each represent a hydrogen atom.
• R 1, R 2 , R 4 and R 5 each represent a hydrogen atom
• R 3 represents NH 2
• X represents -N (R) -, -CH 2 -N (R) -, -N (R) -CH 2 - or -CH 2 -N (R) -CH 2 -
• R represents a group selected from -Ak 2 -Ar ls -Ak 2 -Ari- Ar 2 and -Ak 2 -Ari-0-Ar 2 .
• Another aspect of the present invention relates to the compounds of formula (Ia), a particular case of the compounds of formula (I):
• Ra represents a group selected from -CH 2 -Ari and -CH 2 -Ari-Ar 2 , wherein Ari and Ar 2 are as defined in formula (I).
• the subject of the present invention is also the process for preparing the compounds of formula (I) from the compound of formula (II):
• Y represents a linear or branched C 1 -C 4 alkoxy or dialkylamino group in which the alkyl groups are C 1 -C 4 , linear or branched that is reacted with CO (OG) 2 , where G represents a protecting group of the acid function such as alkyl or benzyl, preferably tert-butyl or benzyl,
• the compound of formula (IV) has at least two asymmetric centers:
• the diastereoisomers of the compound of formula (IV) can be separated using a chiral column, allowing the obtaining of optically pure compounds of formula (I) by the method described above.
• Ga represents a protective group of the amino function such as Boc
• the compound of formula (IVa) has two asymmetric centers:
• the diastereoisomers of the compound of formula (IVa) can be easily separated using a chiral column, allowing the obtaining of optically pure compounds of formula (Ia) by the method described above.
• the compounds of the invention are TAFIa inhibitors.
• thrombotic events are useful in the prevention or treatment of thrombotic events in patients at risk.
• Their use will be of interest in the treatment and prevention of vascular complications, particularly cardiovascular, pulmonary and cerebrovascular complications related to atherothrombotic diseases, atherosclerosis, diabetes, hyperlipidemia, hypertension, chronic venous diseases, metabolic syndrome related to obesity or cancer.
• the compounds according to the invention are particularly useful for the treatment, prevention and secondary prevention of myocardial infarction, angina pectoris, cerebrovascular accidents whatever their origin (especially atherothrombotic, cardioembolism or caused by atrial fibrillation), aortic aneurysms or arteritis of the lower limbs, venous thromboses (especially in the catheterized cancer patient) and pulmonary embolism.
• Vascular risk factors and vascular diseases such as hypertension, obesity, diabetes, heart disease, cerebrovascular disease and hyperlipidemia and therefore atherosclerosis play a role in the genesis of dementia such as the disease Alzheimer's and vascular dementia (Qiu C, De Ronchi D. and Fratiglioni L., The epidemiology of the dementias: an update, 2007, Current Opinion in Psychiatry, 20: 380-385).
• the compounds of the invention will therefore also be useful for the treatment and / or prevention of dementias such as Alzheimer's disease and vascular dementia.
• TAFIa decreases the endogenous fibrinolytic potential.
• the compounds of the present invention are therefore useful for accompanying acute treatment with injectable fibrinolytics, such as recombinant tPA (e.g., alteplase, tenecteplase, reteplase, desmoteplase), recombinant uPA or streptokinase, which are used in emergency situations (eg myocardial infarction, stroke).
• injectable fibrinolytics such as recombinant tPA (e.g., alteplase, tenecteplase, reteplase, desmoteplase), recombinant uPA or streptokinase, which are used in emergency situations (eg myocardial infarction, stroke).
• the compounds of the present invention enhance the activity of these injectable fibrinolytics and therefore lead to their use with less risk haemorrhagic and neurotoxic (reduction of their dose and therefore reduction of their side effects).
• the present invention also relates to pharmaceutical compositions containing a compound of formula (I), in combination with one or more inert, non-toxic, pharmaceutically acceptable excipients or carriers.
• the appropriate dosage varies according to the age and weight of the patient, the route of administration, the nature and severity of the condition, and the possible associated treatments and ranges from 0.5 mg to 1000 mg. one or more shots per day.
• compositions according to the invention mention will be made more particularly of those which are suitable for oral, parenteral (intravenous, intramuscular or subcutaneous), per-or transcutaneous, nasal, rectal, perlingual, ocular or respiratory administration, and in particular single or coated tablets, sublingual tablets, capsules, capsules, suppositories, creams, ointments, dermal gels, injectable or drinkable preparations, aerosols, eye drops or nasal drops.
• the pharmaceutical composition is an injectable preparation for intravenous administration.
• the pharmaceutical composition is a tablet for oral administration.
• the tablets according to the invention contain one or more excipients or carriers such as diluents, lubricants, binders, disintegrating agents, absorbents, colorants, sweeteners.
• excipients or carriers such as diluents, lubricants, binders, disintegrating agents, absorbents, colorants, sweeteners.
• ⁇ for diluents lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycerin,
• ⁇ for lubricants silica, talc, stearic acid and its magnesium and calcium salts, polyethylene glycol,
• ⁇ for the binders magnesium aluminum silicate, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidone,
• ⁇ for disintegrators agar, alginic acid and its sodium salt, effervescent mixtures.
• the percentage of active ingredient of formula (I) in the tablet is preferably between 5% and 50% by weight.
• the compound of formula (I) according to the present invention is administered in combination with a fibrinolytic, more particularly an injectable fibrinolytic such as recombinant tPA (for example, alteplase, tenecteplase, reteplase or desmoteplase), l. recombinant uPA or streptokinase, or with an anticoagulant such as, for example, warfarin, dabigatran etexilate, rivaroxaban.
• a fibrinolytic more particularly an injectable fibrinolytic such as recombinant tPA (for example, alteplase, tenecteplase, reteplase or desmoteplase), l. recombinant uPA or streptokinase, or with an anticoagulant such as, for example, warfarin, dabigatran etexilate, rivaroxaban.
• a fibrinolytic more particularly an injectable fibrino
• the combination administration may be in the form of simultaneous or sequential co-administration of two separate pharmaceutical compositions each containing one of the active ingredients (free association), or in the form of the administration of a fixed combination of the two active ingredients within the same pharmaceutical composition.
• the compound of formula (I) is administered in the form of an injectable preparation, in free association with an injectable preparation of alteplase.
• the compound of formula (I) is administered in the form of an injectable preparation, in free association with an injectable preparation of tenecteplase.
• AIBN azobisisobutyronitrile
• DIBA1H diisobutylaluminum hydride
• EDTA ethylenediaminetetraacetic acid
• HMPA hexamethylphosphoramide
• LiHMDS lithium hexamethyldisilazane or lithium bis (trimethylsilyl) amide
• TAFIa activated thrombin-activatable fibrinolysis inhibitor
• TEA triethylamine
• tPA tissue plasminogen activator
• uPa urokinase plasminogen activator (urokinase plasminogen activator) or urokinase
• hypophosphorous acid (7.42 g, 112 mmol, 1.0 eq) in acetonitrile (160 mL) under argon and at room temperature is added the tetraethylorthosilicate (25 mL, 112 mmol, 1.0 eq).
• the reaction mixture is refluxed for 2 h 30 and then cooled to room temperature.
• the bromoalkene CH 2 CH- (CH 2 ) m + 2-Br (0.5 eq), Pd 2 dba 3 (0.769 g, 0.84 mmol) and the Xantphos (0.356 g, 0.62 mmol) are then added and the reaction mixture is refluxed for 18h.
• the solution is then filtered on filter paper at ambient temperature and concentrated under reduced pressure.
• the crude is purified by flash chromatography on a silica column using a heptane / AcOEt gradient as eluent.
• the Al stage compound is obtained as an oil.
• Example 1 is obtained from intermediate 205 according to procedure A previously described.
• Example 2 is obtained from intermediate 204 according to procedure A previously described.
• Example 4 is obtained from intermediate 206 according to procedure A previously described.
• Example 5 is obtained from intermediate 205 according to procedure A previously described.
• Example 8 is obtained from intermediate 204 according to procedure A previously described.
• Example 9 is obtained from intermediate 209 according to procedure A previously described.
• Example 11 is obtained from N-Boc-4-bromoethylpiperidine according to procedure A previously described.
• Example 12 is obtained from intermediate 208 according to procedure A previously described.
• Example 15 is obtained from Intermediate 212 according to Procedure A previously described.
• Example 16 is obtained from [trans-4- (2-bromoethyl) cyclohexyl] tert-butyl carbamate, according to procedure A previously described.
• Example 17 is obtained from [cis-4- (2-bromoethyl) cyclohexyl] tert-butyl carbamate, according to procedure A previously described.
• Example 18 is obtained from intermediate 206 according to procedure A previously described.
• Example 19 is obtained from intermediate 206 according to procedure A previously described.
• Example 20 (0.209 g, 0.591 mmol) is obtained as a white solid after lyophilization with a yield of 80%.
• Example 24 is obtained from intermediate 20a according to procedure D previously described.
• Example 25 is obtained according to the procedure D previously described from intermediate 20b.
• Example 26 is obtained from intermediate 20c according to procedure D previously described.
• Example 28 is obtained from intermediates 19 and 212 according to procedures C and D previously described without intermediate purification.
• Example 29 is obtained from the intermediate 20e according to the procedure D previously described.
• Example 30 is obtained from intermediate 20f according to procedure D previously described.
• a solution of intermediate 19 (50 g, 141.5 mmol) in DMSO (120 mL) is then added dropwise keeping the temperature below 20 ° C.
• 100 mL of anhydrous THF are then added to maintain agitation.
• the reaction mixture is cooled with an ice-water bath and hydrolysed by adding 500 ml of a solution saturated with NH 4 Cl.
• the mixture is then extracted with AcOEt (3 x 300 mL).
• the organic phases are then combined, washed with saturated NaCl solution (2 x 300 mL), and dried over MgSO 4 before being concentrated under reduced pressure.
• the yellowish residue (92.5 g) thus obtained is then purified by chromatography on silica gel using a CH 2 Cl 2 / AcOEt / MeOH mixture as eluent.
• the expected product (69.3 g, 110.9 mmol), a mixture of 4 diastereoisomers, is obtained in the form of a white solid with a yield of 78%.
• the filtrate is evaporated to dryness in order to obtain a yellow oil which is taken up in AcOEt (400 mL) and a solution of 10% NaHCO 3 (400 mL). After decantation, the aqueous phase is extracted with AcOEt (3 x 100 mL). The organic phases are combined and then washed with saturated NaCl solution (400 ml), dried over MgSO 4 and concentrated to yield the expected intermediate 21 in the form of a white solid (57.6 g, 107.7 mmol) in a yield of 91%.
• Procedure L Procedure for the Synthesis of Ar 2 -Ari-CHO Aldehydes by a Suzuki Coupling
• the non-commercial aldehydes were prepared according to the procedure described below:
• Example 32 is obtained from intermediate 22 according to the procedure D previously described.
• Example 34 is obtained from intermediate 24 according to the procedure D previously described.
• Example 35 is obtained from Intermediate 25 according to Procedure D previously described.
• Example 36 is obtained from intermediate 26 according to procedure D previously described.
• Example 37 is obtained from intermediate 27 according to the procedure D previously described.
• Example 38 is obtained from intermediate 28 according to procedure D previously described.
• Example 39 is obtained from intermediate 29 according to the procedure D described above.
• Example 41 is obtained from intermediate 31 according to the procedure D previously described.
• Example 42 is obtained from intermediate 32 according to procedure D previously described.
• Example 43 is obtained from intermediate 33 according to the procedure D previously described.
• Example 44 is obtained from Intermediate 34 according to Procedure D previously described.
• Example 45 is obtained from intermediate 35 according to procedure D previously described.
• Example 46 is obtained from intermediate 36 according to procedure D previously described.
• Example 47 is obtained from Intermediate 37 according to Procedure D previously described.
• Example 48 is obtained from Intermediate 38 according to Procedure D previously described.
• Example 49 is obtained from intermediate 39 according to procedure D previously described.
• Intermediate 40 is obtained from intermediates 21 and 240 according to procedure F previously described.
• Example 50 is obtained from intermediate 40 according to the procedure D previously described.
• Example 52 is obtained from Intermediate 42 according to Procedure D previously described.
• Example 53 is obtained from intermediate 43 according to the procedure D previously described.
• Example 54 is obtained from intermediate 44 according to procedure D previously described.
• Example 56 is obtained from intermediate 46 according to procedure D previously described.
• Example 57 is obtained from intermediate 47 according to procedure D previously described.
• Example 58 is obtained from intermediate 48 according to procedure D previously described.
• Example 61 is obtained from intermediate 51 according to the procedure D previously described.
• Example 62 is obtained from Intermediate 52 according to Procedure D previously described.
• Example 63 is obtained from intermediate 53 according to the procedure D previously described.
• Example 64 is obtained from Intermediate 54 according to Procedure D previously described.
• Example 55 is obtained from intermediate 65 according to procedure D previously described.
• Example 67 is obtained from Intermediate 57 according to Procedure D previously described.
• Example 68 is obtained from Intermediate 58 according to Procedure D previously described.
• Example 70 is obtained from intermediate 60 according to procedure D previously described.
• Example 73 is obtained from intermediate 63 according to the procedure D previously described.
• Example 74 is obtained from intermediate 64 according to the procedure D previously described.
• Example 76 is obtained from Intermediate 66 according to Procedure D previously described.
• Example 79 is obtained from intermediate 21 and benzyloxyacetaldehyde according to procedures F and D previously described.
• Example 80 is obtained from Example 79 according to the procedure E described above.
• Example 82 is obtained from intermediate 70 according to the procedure D previously described.
• Example 83 is obtained from intermediate 71 according to the procedure D previously described.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Neurosurgery (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Hospice & Palliative Care (AREA)
• Psychiatry (AREA)
• Hematology (AREA)
• Diabetes (AREA)
• Dermatology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Other In-Based Heterocyclic Compounds (AREA)

Priority Applications (33)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=55752640

Family Applications (1)

Country Status (47)

Families Citing this family (1)

Citations (1)

Family Cites Families (11)

• 2016
  • 2016-01-14 FR FR1670004A patent/FR3046793B1/fr not_active Expired - Fee Related
  • 2016-12-27 JO JOP/2016/0275A patent/JO3660B1/ar active
• 2017
  • 2017-01-11 UY UY0001037072A patent/UY37072A/es unknown
  • 2017-01-12 TW TW106100930A patent/TWI625334B/zh not_active IP Right Cessation
  • 2017-01-12 AR ARP170100074A patent/AR107433A1/es unknown
  • 2017-01-13 PT PT17706525T patent/PT3271368T/pt unknown
  • 2017-01-13 UA UAA201808634A patent/UA121275C2/uk unknown
  • 2017-01-13 JP JP2018536455A patent/JP2019504070A/ja active Pending
  • 2017-01-13 MD MDE20180097T patent/MD3271368T2/ro not_active IP Right Cessation
  • 2017-01-13 CU CUP2018000072A patent/CU20180072A7/es unknown
  • 2017-01-13 EA EA201891599A patent/EA035072B1/ru not_active IP Right Cessation
  • 2017-01-13 RU RU2018129027A patent/RU2729641C2/ru not_active IP Right Cessation
  • 2017-01-13 MX MX2018008639A patent/MX367319B/es active IP Right Grant
  • 2017-01-13 GE GEAP201714853A patent/GEP20207092B/en unknown
  • 2017-01-13 CN CN201780008078.XA patent/CN108495857A/zh active Pending
  • 2017-01-13 CA CA3011184A patent/CA3011184C/fr not_active Expired - Fee Related
  • 2017-01-13 HK HK18103808.6A patent/HK1244283B/zh not_active IP Right Cessation
  • 2017-01-13 PL PL17706525T patent/PL3271368T3/pl unknown
  • 2017-01-13 ME MEP-2019-23A patent/ME03305B/me unknown
  • 2017-01-13 HR HRP20190193TT patent/HRP20190193T1/hr unknown
  • 2017-01-13 DK DK17706525.7T patent/DK3271368T3/da active
  • 2017-01-13 BR BR112018014020-1A patent/BR112018014020A2/pt not_active IP Right Cessation
  • 2017-01-13 SG SG11201805757WA patent/SG11201805757WA/en unknown
  • 2017-01-13 HU HUE17706525A patent/HUE042924T2/hu unknown
  • 2017-01-13 US US15/548,533 patent/US10138260B2/en not_active Expired - Fee Related
  • 2017-01-13 SI SI201730013T patent/SI3271368T1/sl unknown
  • 2017-01-13 TR TR2018/20430T patent/TR201820430T4/tr unknown
  • 2017-01-13 WO PCT/FR2017/050075 patent/WO2017121969A1/fr not_active Ceased
  • 2017-01-13 EP EP17706525.7A patent/EP3271368B1/fr active Active
  • 2017-01-13 LT LTEP17706525.7T patent/LT3271368T/lt unknown
  • 2017-01-13 KR KR1020187023228A patent/KR20180101522A/ko not_active Abandoned
  • 2017-01-13 AU AU2017207003A patent/AU2017207003B2/en not_active Expired - Fee Related
  • 2017-01-13 RS RS20190105A patent/RS58338B1/sr unknown
  • 2017-01-13 MA MA41798A patent/MA41798B1/fr unknown
  • 2017-01-13 PE PE2018001210A patent/PE20181503A1/es unknown
  • 2017-01-13 ES ES17706525T patent/ES2709376T3/es active Active
  • 2017-01-13 TN TNP/2018/000226A patent/TN2018000226A1/fr unknown
• 2018
  • 2018-06-26 PH PH12018501373A patent/PH12018501373A1/en unknown
  • 2018-06-29 ZA ZA2018/04391A patent/ZA201804391B/en unknown
  • 2018-07-04 IL IL260425A patent/IL260425B/en active IP Right Grant
  • 2018-07-05 SV SV2018005721A patent/SV2018005721A/es unknown
  • 2018-07-06 NI NI201800073A patent/NI201800073A/es unknown
  • 2018-07-09 DO DO2018000165A patent/DOP2018000165A/es unknown
  • 2018-07-09 CL CL2018001862A patent/CL2018001862A1/es unknown
  • 2018-07-11 EC ECSENADI201851972A patent/ECSP18051972A/es unknown
  • 2018-07-12 CO CONC2018/0007271A patent/CO2018007271A2/es unknown
  • 2018-10-04 US US16/151,597 patent/US10654878B2/en not_active Expired - Fee Related
  • 2018-12-10 CY CY20181101320T patent/CY1121154T1/el unknown

Patent Citations (1)

Also Published As

Similar Documents

Legal Events